Knowledge Resource Center for Ecological Environment in Arid Area
DOI | 10.1161/CIRCULATIONAHA.108.789479 |
Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials | |
Mehta, Shamir R.1,2; Boden, William E.3,4; Eikelboom, John W.1,2; Flather, Marcus5; Steg, Gabriel; Avezum, Alvaro7; Afzal, Rizwan; Piegas, Leopoldo S.7; Faxon, David P.8; Widimsky, Petr9; Budaj, Andrzej10; Chrolavicius, Susan1,2; Rupprecht, Hans-Jurgen12; Jolly, Sanjit1,2; Granger, Christopher B.13; Fox, Keith A. A.11; Bassand, Jean-Pierre14; Yusuf, Salim1,2 | |
通讯作者 | Mehta, Shamir R. |
来源期刊 | CIRCULATION
![]() |
ISSN | 0009-7322 |
EISSN | 1524-4539 |
出版年 | 2008 |
卷号 | 118期号:20页码:2038-2046 |
英文摘要 | Background - The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST- and ST-segment elevation acute coronary syndromes, respectively. Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported. Methods and Results - We performed an individual patient - level combined analysis of 26 512 patients from the OASIS 5 and 6 trials who were randomized in a double-blind fashion to fondaparinux 2.5 mg daily or a heparin-based strategy (dose-adjusted unfractionated heparin or enoxaparin). Results were stratified according to whether an early invasive, a delayed invasive, or an initial conservative management strategy was performed. Fondaparinux was superior to heparin in reducing the composite of death, myocardial infarction, or stroke (8.0% versus 7.2%; hazard ratio [HR], 0.91; P = 0.03) and death alone (4.3% versus 3.8%; HR, 0.89; P = 0.05). Fondaparinux reduced major bleeding by 41% (3.4% versus 2.1%; HR, 0.59; P < 0.00001) and had a more favorable net clinical outcome than heparin (11.1% versus 9.3%; HR, 0.83; P < 0.0001). In 19 085 patients treated with an invasive strategy, fondaparinux suppressed ischemic events to an extent similar to heparin and reduced major bleeding by more than one-half, resulting in a superior net clinical outcome (10.8% versus 9.4%; HR, 0.87; P = 0.008). A similar benefit also was observed in those treated with a conservative strategy (HR, 0.74; 95% confidence interval, 0.64 to 0.85; P < 0.001). Conclusion - Compared with a heparin-based strategy, fondaparinux reduced mortality, ischemic events, and major bleeding across the full spectrum of acute coronary syndromes and was associated with a more favorable net clinical outcome in patients undergoing either an invasive or a conservative management strategy. (Circulation. 2008; 118: 2038-2046.) |
英文关键词 | acute coronary syndrome angina unstable anticoagulants heparin meta-analysis myocardial infarction |
类型 | Article |
语种 | 英语 |
国家 | Canada ; USA ; England ; France ; Brazil ; Czech Republic ; Poland ; Scotland ; Germany |
收录类别 | SCI-E |
WOS记录号 | WOS:000260795800005 |
WOS关键词 | MOLECULAR-WEIGHT HEPARIN ; MYOCARDIAL-INFARCTION ; UNFRACTIONATED HEPARIN ; TASK-FORCE ; ENOXAPARIN ; EFFICACY ; METAANALYSIS ; BIVALIRUDIN ; SOCIETY ; ROUTINE |
WOS类目 | Cardiac & Cardiovascular Systems ; Peripheral Vascular Disease |
WOS研究方向 | Cardiovascular System & Cardiology |
资源类型 | 期刊论文 |
条目标识符 | http://119.78.100.177/qdio/handle/2XILL650/156879 |
作者单位 | 1.McMaster Univ, Hamilton, ON, Canada; 2.Populat Hlth Res Inst, Hamilton, ON, Canada; 3.SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA; 4.SUNY Buffalo, Sch Publ Hlth, Buffalo, NY 14260 USA; 5.Royal Brompton & Harefield NHS Trust, London, England; 6.Hop Bichat Claude Bernard, F-75877 Paris 18, France; 7.Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil; 8.Brigham & Womens Hosp, Boston, MA 02115 USA; 9.Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; 10.Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland; 11.Univ Edinburgh, Royal Infirm Edinburgh, Edinburgh, Midlothian, Scotland; 12.Second Med Clin, Russelsheim, Germany; 13.Duke Clin Res Inst, Durham, NC USA; 14.Univ Hosp Jean Minjoz, Besancon, France |
推荐引用方式 GB/T 7714 | Mehta, Shamir R.,Boden, William E.,Eikelboom, John W.,et al. Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials[J],2008,118(20):2038-2046. |
APA | Mehta, Shamir R..,Boden, William E..,Eikelboom, John W..,Flather, Marcus.,Steg, Gabriel.,...&Yusuf, Salim.(2008).Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials.CIRCULATION,118(20),2038-2046. |
MLA | Mehta, Shamir R.,et al."Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials".CIRCULATION 118.20(2008):2038-2046. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。